Fiserv earnings missed by $0.61, revenue fell short of estimates
Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA BIO, Inc. (NASDAQ:KALA), sold 46,748 shares of common stock on October 22, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the transaction amounted to $38800. The sale comes as KALA trades near its 52-week low, with the stock down approximately 81% year-to-date. According to InvestingPro analysis, the company currently has a market capitalization of just $5.6 million.
The shares were sold at a weighted average price of $0.83, in multiple transactions at prices ranging from $0.82 to $0.85. Following the transaction, Brazzell directly owns 35,952 shares, which includes 35,952 unvested restricted stock units (RSUs). InvestingPro analysis indicates the stock is currently undervalued, with 17 additional key insights available to subscribers, including detailed metrics on the company’s financial health and market position.
In other recent news, Kala Bio, Inc. has faced several significant developments. The company received a default notice from Oxford Finance LLC, declaring a $29.1 million loan immediately due, as per their Loan and Security Agreement. This notice, issued under the agreement’s Material Adverse Change clause, suggests ongoing and potential additional defaults. Additionally, Kala Bio’s CHASE Phase 2b clinical trial for the KPI-012 treatment failed to meet its primary and secondary endpoints for persistent corneal epithelial defect (PCED). This result has led the company to halt the development of both KPI-012 and its mesenchymal stem cell secretome platform. Analysts from Mizuho have noted the lack of detailed data from the trial and expect weakness in Kala Bio’s stock following these results. Furthermore, Kala Bio has scheduled its 2025 annual shareholder meeting for December 11, with more details to be provided in a forthcoming proxy statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.